CATX
Perspective Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Perspective Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No thesis.
Largest filed tie
0
filed ties
Annual filing, covered
10-K parsed · Mar 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 16 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $32.4M | 10.88% | +77.51% |
| TCG Crossover | $27.0M | 9.07% | 0.00% |
| Commodore Capital | $21.6M | 7.26% | 0.00% |
| Avidity Partners | $21.5M | 7.22% | −47.93% |
| State Streetindex-like | $20.6M | 6.93% | +93.18% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $32.4M | 10.88% | +77.51% |
| TCG Crossover | $27.0M | 9.07% | 0.00% |
| Commodore Capital | $21.6M | 7.26% | 0.00% |
| Avidity Partners | $21.5M | 7.22% | −47.93% |
| State Streetindex-like | $20.6M | 6.93% | +93.18% |
+6.00%
vs ±21.1% implied · ×0.28
shaded = implied · ▲▼ = realized
Bull2
Bear2
Perspective Therapeutics, Inc.
0.86
−0.02 · −2.72%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Perspective Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Perspective Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.